Loading...
Loading...

Go to the content (press return)

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study

Author
Muñoz-Moreno, J.A.; Prats, A.; Molto, J.; Garolera, M.; Perez, N.; Díez, C.; Miranda, C.; Fumaz, C.R.; Ferrer, M.; Clotet, B.
Type of activity
Journal article
Journal
PloS one
Date of publication
2017-08-30
Volume
12
Number
8
First page
1
Last page
14
DOI
https://doi.org/10.1371/journal.pone.0182547 Open in new window
URL
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182547 Open in new window
Abstract
Objective To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-associated cognitive impairment. Methods We recruited HIV-infected patients with cognitive impairment on stable antiretroviral therapy in a randomized controlled pilot trial with a 48-week follow-up. An additional assessment was held at 12 weeks. Participants received transdermal rivastigmine (9.5 mg daily), lithium (400 mg twice daily, titrated progressively), or remained in a control group (no n...
Group of research
GRBIO - Biostatistics and Bioinformatics Research Group

Participants

  • Muñoz Moreno, Jose Antonio  (author)
  • Prats París, Anna  (author)
  • Molto Marhuenda, Jose  (author)
  • Garolera Freixa, Maite  (author)
  • Perez Alvarez, Nuria  (author)
  • Díez Quevedo, Crisanto  (author)
  • Miranda, Cristina  (author)
  • Rodriguez Fumaz, Carmina  (author)
  • Ferrer Lasala, Maria Jose  (author)
  • Clotet Sala, Bonaventura  (author)